Actively Recruiting
Comparing Intralesional Triamcinolone and Candida Albicans Antigen for Treating Alopecia Areata in Patients Over 6 Years Old
Led by Universidad Autonoma de Nuevo Leon · Updated on 2024-08-21
30
Participants Needed
1
Research Sites
22 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of two intralesional treatments for alopecia areata in patients over 6 years old with less than 50% scalp involvement. This trial aims to compare the standard treatment, intralesional Triamcinolone, with a Candida albicans antigen injection to see which better improves hair loss and to monitor related side effects. Participants will receive either Triamcinolone acetonide injections at a concentration of 4 mgmL, administered in 0.1 mL doses spaced 1 cm apart up to a maximum of 3 mL per session, or a single 0.1 mL subcutaneous injection of Candida albicans antigen into an alopecic patch. The treatments are given in a randomized, triple-masked way to fairly compare their effects. During the 5-month follow-up, participants will have clinical and trichoscopic photos taken regularly to assess treatment response and monitor any side effects. The study will carefully evaluate how each treatment affects hair regrowth and safety over this period, with all assessments conducted under medical supervision.
CONDITIONS
Brief Title
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Research Team
E
Erika Alba-Rojas, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
